Changes in [18F]Fluoro-2-deoxy-d-glucose incorporation induced by doxorubicin and anti-HER antibodies by breast cancer cells modulated by co-treatment with metformin and its effects on intracellular signalling | Zendy

Alasdair C. Cooper | Zendy; Ian N. Fleming | Zendy; Su Phyu | Zendy; Timothy Smith | Zendy

Open Access

Changes in [18F]Fluoro-2-deoxy-d-glucose incorporation induced by doxorubicin and anti-HER antibodies by breast cancer cells modulated by co-treatment with metformin and its effects on intracellular signalling

Author(s) -

Alasdair C. Cooper,

Ian N. Fleming,

Su Phyu,

Timothy Smith

Publication year - 2015

Publication title -

journal of cancer research and clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.338

H-Index - 94

eISSN - 1432-1335

pISSN - 0171-5216

DOI - 10.1007/s00432-015-1909-2

Subject(s) - metformin , skbr3 , breast cancer , ampk , doxorubicin , pharmacology , medicine , mapk/erk pathway , trastuzumab , cancer , mcf 7 , cancer cell , cancer research , endocrinology , chemistry , chemotherapy , phosphorylation , protein kinase a , biochemistry , insulin , human breast

Metformin, currently undergoing clinical trials as an adjuvant for the treatment of breast cancer, modulates the activity of key intracellular signalling molecules which affect 2-[(18)F]Fluoro-2-deoxy-D-glucose ([(18)F]FDG) incorporation. Here, we investigate the effect of drugs used in the treatment of breast cancer combined with metformin on [(18)F]FDG incorporation in HER2- or HER1-overexpressing breast cancer cells to determine whether or not metformin may obscure changes in [(18)F]FDG incorporation induced by clinically utilised anticancer drugs in the treatment of breast cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research